骨髓增生异常综合征(myelodysplastic syndrome,MDS)是一组异质性造血干细胞疾病,其特征是无效造血、发育异常、外周血细胞减少、进展性骨髓衰竭及向急性髓系白血病(acute myelogenous leukemia,AML)转化的高风险性~[1-2]。MDS患者的血小板减少发生率为40%~65%~[3],且有14%~30%的患者直接死于血小板减少导致的出血~[4]。由血小板减少导致的出血并发症是MDS患者死亡的主要原 Myelodysplastic syndrome (MDS) is a heterogeneous group of hematopoietic stem cell disorders characterized by ineffective hematopoiesis, dysplastic development, peripheral pancytopenia, progressive bone marrow failure, and acute myelogenous leukemia (AML) ) High risk of conversion ~ [1-2]. The incidence of thrombocytopenia in MDS patients is 40% -65%. [3], and 14% -30% of patients die directly from thrombocytopenia-induced bleeding. [4] Hemorrhagic complications caused by thrombocytopenia are the major causes of death in MDS patients